<DOC>
	<DOCNO>NCT01176916</DOCNO>
	<brief_summary>Aromasin® ( Exemestane ) approve China adjuvant treatment postmenopausal woman estrogen receptor ( ER ) positive early invasive breast cancer receive 2-3 year tamoxifen &amp; switch Aromasin® completion total 5 consecutive year adjuvant hormonal therapy State Food Drug Administration ( SFDA ) clinical trial waive . While Aromasin® use China adjuvant therapy breast cancer since , currently lack systematic collection analysis efficacy safety data Aromasin® adjuvant set Chinese population . The Aromasin® Non-Interventional Study propose collect data systematically assess efficacy safety Aromasin® adjuvant set Chinese population .</brief_summary>
	<brief_title>Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China</brief_title>
	<detailed_description>This non-interventional study single arm study . N/A</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Early invasive breast cancer ( T14N13M0 ) confirm histology cytology . ER positive . The patient must postmenopausal woman . The patient receive adjuvant Tamoxifen therapy 23 year switch receive Aromasin® treatment ( The decision prescribe Aromasin® necessarily precede independent decision enroll patient study ) . Following adjuvant Tamoxifen therapy 23 year prior receive Aromasin® treatment , evidence local relapse distant metastasis breast cancer , second primary cancer . Following adjuvant Tamoxifen therapy 23 year receive aromatase inhibitor ( Aromasin® ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>Aromasin</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>endocrine therapy</keyword>
</DOC>